Daniel Okafor
Research Analyst
Daniel tracks registered trials and new publications across the peptide space. His beat is evidence quality: what a study actually measured, how many subjects it had, and what it cannot tell you yet.
Tirzepatide Versus Dulaglutide in Heart Disease and Diabetes
A new SURPASS CVOT analysis compares tirzepatide and dulaglutide in diabetes patients with heart disease.
Oxytocin Peptide Research Overview: What Studies Show About Social Bonding and Metabolic Health
A data first look at what oxytocin research actually shows about bonding, stress, appetite, and metabolic markers.
FDA Approves Pirtobrutinib for Untreated CLL and SLL
FDA approved pirtobrutinib for adults with previously untreated CLL or SLL lacking the 17p deletion, based on a randomized trial.
SURMOUNT J Looks At Belly Fat Changes With Tirzepatide
A SURMOUNT J substudy examines how tirzepatide affects abdominal fat and metabolic markers in Japanese adults with obesity.
Retatrutide: The Triple Agonist in Clinical Trials
Retatrutide is an investigational triple hormone receptor agonist showing large weight loss results in phase 2 and phase 3 trials.
FDA Moves to Prevent Newborn Nutrition Shortage
FDA issued temporary compounding guidance to prevent a supply gap in starter IV nutrition for premature newborns.
Sermorelin Research Overview: What Studies Show About This GHRH Peptide
A data first look at what published studies show about sermorelin, a GHRH peptide studied for growth hormone and IGF 1 signaling.
Retatrutide Phase 3 Trial Reports Major Weight Loss Data
TRIUMPH 1, a large Phase 3 trial, found retatrutide cut body weight by up to 28.3% over 80 weeks.
BPC-157 Research Overview: What the Evidence Shows
BPC-157 is an investigational peptide studied mostly in animals for tissue repair, not an approved human therapy.